Floatz logo

Gfb-024

Diabetes Complications

Goldfinch Bio, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Diabetes Complications cohort.

Asset / SponsorPhaseRating
Exenatide
University of California, Davis
Phase 2CCC
Omnipaque
University of Colorado, Denver
Phase 1/2CCC
SODIUM P-AMINOHIPPURATE
University of Colorado, Denver
Phase 1/2CCC
Primepro™/ Primemsk™
Thomas Advanced Medical LLC
Phase 1/2CCC

Same molecule, other indications

Gfb-024 is also rated in:

kidney disorderDormant
CC
Indicative ·
47 / 100
View asset →
diabetic kidney diseaseDormant
CC
Indicative ·
47 / 100
View asset →
endocrine system disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →